The present invention discloses that the intestinal metagenomic feature is used as a screening marker for the effect of treating acarbose in type 2 diabetes, and the intestinal microbial macrogen feature is Bacteroides intestinal type. In the present invention, by first using the concept of intestinal type, in type 2 diabetic patients with different intestinal parasitic fungal groups, it was discovered that the therapeutic effect on diabetes hypoglycemic drug, acarbose, was significantly different. Before using the medicine, the optimal treatment effect group is selected by dividing the intestinal type of the patient, and whether or not the individual type 2 diabetic patient is treated with diabetes using acarbose I can judge. In addition, in the normal classification of intestinal type, sequence measurement or PCR expansion using fecal parasite DNA is performed, but bile acid components, especially secondary bile acids, are not detected against intestinal type under baseline conditions. Since it has a good classification role and can realize differentiation of intestinal type through markers in blood, it is a marker used for diagnosis. [Selection] Figure 2
展开▼
